NSCLC Coverage From Every Angle
Advertisement
Advertisement

Recent News

Is More Frequent Surveillance Associated With Better Survival for Patients With NSCLC?
FDA Approves Atezolizumab Combination in First-Line Treatment of Metastatic Nonsqumous NSCLC
Radiation-Based Trimodality Therapy in Stage III NSCLC
Combined Immunotherapy Treatment Studied in Advanced Lung Cancer
Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors
FDA Approves Larotrectinib in Solid Tumors With NTRK Gene Fusion
Palliative and Supportive Care Symposium: Immunotherapy-Related Toxicities
ESMO 2018: Neoadjuvant Erlotinib in Stage IIIA-N2 Lung Cancer
ESMO 2018: Single-Agent Nazartinib in EGFR-Mutant Lung Cancer
ASTRO 2018: Nelfinavir in Stage III Locally Advanced Lung Cancer
ESMO 2018: Resistance Mechanisms in Patients Treated with Osimertinib for Lung Cancer
ESMO 2018: Uncommon EGFR Mutations in Lung Adenocarcinoma
FDA Approves Lorlatinib in ALK-Positive Metastatic NSCLC
FDA Approves Pembrolizumab With Chemotherapy as First-Line Treatment of Metastatic NSCLC
Are Immune-Related Adverse Events Similar in Men and Women?
ASTRO 2018: Survival Benefit Reported With Local Consolidative Therapy in Oligometastatic NSCLC
ESMO 2018: Early Results With Novel Monoclonal Antibody in Advanced Lung Cancer
ESMO 2018: Benefit From Exercise Reported in Advanced Lung Cancer
WCLC 2018: Poziotinib in NSCLC With Genetic Mutations
CHEST 2018: Update on Adherence to Lung Cancer Screening
WCLC 2018: Brigatinib Poised to Become New First-Line Treatment in ALK-Positive Lung Cancer
WCLC 2018: Smoking Cessation Services During Lung Cancer Screening
WCLC 2018: Lorlatinib Active in ROS1-Positive NSCLC
International Cancer Immunotherapy Conference: Early Study Results of Vaccine in HER2-Positive Cancers
WCLC 2018: Survival Benefit With Durvalumab After Chemoradiotherapy in Stage III NSCLC
WCLC 2018: Effect of Nivolumab on Intracerebral Response in NSCLC With Brain Metastases
WCLC 2018: Survival Benefit in Women Compared With Men
WCLC 2018: Immunotherapy for Lung Cancers With Oncogenic Driver Mutations
Dacomitinib Approved by the FDA for Metastatic NSCLC With Genetic Mutations
WCLC 2018: Entrectinib in ROS1-Positive NSCLC
WCLC 2018: Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Early-Stage Disease
FDA Grants Priority Review to Pembrolizumab as First-Line Treatment in NSCLC Subset
Can m-TORC1/2 Inhibitor Added to Chemotherapy Improve Outcomes in Lung Cancer?
New Therapeutic Strategy for KRAS-Dependent Lung Cancer
RET Inhibitor for NSCLC Granted Breakthrough Therapy Designation by FDA
Can Liquid Biopsy Predict Benefit From Immunotherapy in Lung Cancer?
Building MRI Videos for Planning Lung Cancer Radiotherapy
FDA Approves EGFR-Mutation Test for Use With Gefitinib in NSCLC
Study Reports Upside to Adverse Events With Nivolumab Treatment of NSCLC
FDA Approves Pembrolizumab Plus Chemotherapy as First-Line Treatment of NSCLC
Are Lung Cancer Screening Guidelines Adequate for High-Risk Minorities?
IASLC Unveils Comprehensive Assessment of Liquid Biopsy for Patients With NSCLC
Can Simplified Screening Methods Accurately Indicate Pathology in NSCLC?
World Lung Cancer Day Commemorated by International Respiratory Societies
Novel Vaccine for Lung Cancer Moves Into Phase I Clinical Trial
Is Physical Inactivity Linked to Lung Cancer Risk?
Alectinib Versus Crizotinib in Advanced ALK-Positive Lung Cancer
Who Has Higher Incidence of Lung Cancer in United States: Young Women or Young Men?
Study Results Support Survival Benefit of Atezolizumab-Based Therapy in NSCLC
FDA Expands Approval of Pembrolizumab for First-Line Treatment of NSCLC
Long Noncoding RNAs as Potential Biomarkers in Non–Small Cell Lung Cancer
FDA Accepts Application for First-Line Combination Immunotherapy in Subgroup With NSCLC
ASCO 2018: Safety Analysis of First-Line Nivolumab Plus Ipilimumab for Advanced NSCLC
Projected Lung Cancer Rates in Patients Living With HIV
Combined Effects of FLT3 Ligand and Stereotactic Radiotherapy In Lung Cancer
ASCO 2018: Potential New Standard of Care in Pembrolizumab Combination for Advanced Squamous NSCLC


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.